CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
启动四线及以后 CAR-T 细胞或双特异性抗体治疗的复发/难治性多发性骨髓瘤患者的预后因素：系统文献综述与荟萃分析
英文原题：Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.
查看英文原题
Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
本研究强调了通过系统且透明的过程识别的预后因素，这些因素可能影响 ITCs 以及后线多发性骨髓瘤的政策决策。
中文摘要
方法
系统检索MEDLINE、EMBASE、CENTRAL及相关学术会议，纳入评估CAR-T 细胞和/或BsAb疗法的试验及观察性研究。纳入研究需报告潜在因素与疗效、生存和/或安全性结局的关系。采用荟萃分析汇总总体及按治疗类别分层的因素-结局关联。
结果
在102篇文献（43项研究）中，可对15项潜在因素进行分析。发现具有统计学显著性的因素-结局关联，包括年龄、细胞遗传学风险、ECOG体能状态、ISS/R-ISS分期、骨髓浆细胞负荷、髓外病变、铁蛋白、既往抗BCMA治疗及三类药物难治状态。关联因结局指标而异，部分情况下也因治疗类别而不同。
结论
本研究通过系统且透明的流程识别预后因素，提示这些因素可能影响ITC及后线多发性骨髓瘤治疗的政策决策。 注册：PROSPERO（CRD42023446880）。注册前仅开展了试点工作，未进行正式综述或数据收集。
展开英文摘要原文
METHODS
A systematic literature review of MEDLINE, EMBASE, CENTRAL, and pertinent conferences for trials and observational studies evaluating CAR T-cell and/or BsAb therapies. Eligible studies presented potential factors in relation to efficacy, survival, and/or safety outcomes. Meta-analyses summarized factor-outcome associations, overall and by treatment class.
RESULTS
From 102 publications (43 studies), analyses were feasible for 15 potential factors. Statistically significant factor-outcome dyads were identified, including factors of age, cytogenetic risk, ECOG PS, ISS/R-ISS stage, bone marrow plasma cell burden, extramedullary disease, ferritin, prior anti-BCMA exposure, and triple-class refractory status. Associations varied by outcome and, in some cases, by treatment class.
CONCLUSIONS
This study highlights prognostic factors, identified through a systematic and transparent process, that may influence ITCs and policy decision-making in later-line multiple myeloma. REGISTRATION: PROSPERO (CRD42023446880). Only pilot work and no formal review or data collection occurred prior to the registration.
论文信息
- 作者
- Patel K、Hasegawa K、Ting J、Sidana S、Zoratti MJ、Wennersbusch D、Kanters S、Kostic A
- 第一作者单位
- Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.United States
- 通讯作者单位
- Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.United States
- 文献类型
- 系统综述 · 荟萃分析 · 综述
- 期刊
- Expert review of hematology2026 Sep
- 原文标识
- PubMed 42269717 · DOI 10.1080/17474086.2026.2688385